| Trial ID # | NCT05123482 |
| Phase | I/IIa |
| Drug Class | Antibody Drug Conjugates: B7H4 |
| Drug Name | Puxitatug samrotecan |
| Alternate Drug Names | AZD8205 |
| Drugs in Trial | Puxitatug samrotecan |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 47 patients in dose escation, median 5 prior therapies (2-9); 17 OC |
| Therapy Setting | Recurrence |
| Efficacy | ORR: 17.6% (3PR) |
| Conclusion | Puxitatug samrotecan (AZD8205) has a manageable safety profile consistent with other Topoisomerase 1 inhibitor ADCs and shows preliminary efficacy in heavily pretreated patients with prior progression on standard treatment |
| Reference | Meric-Bernstam F et al. Initial results from a first-in-human study of the B7-H4- directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors. Ann Oncol (2024) 35 (2) abstract 606O |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.